Gilead receives legal fees from the Hepatitis C patent dispute with Merck
A U.S. district court judge ruled that Gilead Sciences Inc has a claim to the reimbursement of legal incurred from the Hepatitis C litigation with the pharmaceutical company Merck & Co.Inc.
In June, Gilead, from a compensation payment in the amount of $ has been freed 200 million for infringement of two patents of Merck in connection with the Blockbuster drugs amendments classroom and Harvoni from Gilead, after a US judge for a pattern of misconduct on the part of Merck, including perjury and other unethical actions, revealed.
In the case of filing of the suit on Thursday, U.S. Magistrate Beth Labson Freeman said that Gilead has the right to the remission of costs incurred during the defense of the case.
Merck tried with Gilead, which dominates the market of a new Generation of Hepatitis C drugs that can cure over 90 percent of patients with liver disease.
The case goes back to the year 2013, Gilead, and Merck took each other Respondent and the property on the laboratory work, which Sofosbuvir underlying, the active ingredient in the medication from Gilead.
